Stoke's Dravet syndrome med released from partial clinical hold as company eyes phase 3 plans

Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program.

While studies for STK-001, now known as zorevunersen, had continued on for certain doses, Stoke can now test multiple doses above 45 mg.